The stock of Leap Therapeutics Inc. (NASDAQ:LPTX) last traded at $0.42, down -3.00% from the previous session.
Data from the available sources indicates that Leap Therapeutics Inc. (NASDAQ:LPTX) is covered by 5 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $2.50, we find $4.00. Given the previous closing price of $0.43, this indicates a potential upside of 830.23 percent. LPTX stock price is now -34.43% away from the 50-day moving average and -62.39% away from the 200-day moving average. The market capitalization of the company currently stands at $40.67M.
In total, 0 analysts have assigned it a hold rating, and 3 have given it a buy rating. Brokers who have rated the stock have averaged $4.10 as their price target over the next twelve months.
With the price target of $6, Mizuho recently initiated with Buy rating for Leap Therapeutics Inc. (NASDAQ: LPTX)., while ‘Piper Sandler’ rates the stock as ‘Overweight’.
A total of 9.26% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in LPTX stock. A new stake in Leap Therapeutics Inc. shares was purchased by TRI LOCUM PARTNERS LP during the first quarter worth $299,000. JANE STREET GROUP, LLC invested $55,000 in shares of LPTX during the first quarter. In the first quarter, GSA CAPITAL PARTNERS LLP acquired a new stake in Leap Therapeutics Inc. valued at approximately $23,000. ANNANDALE CAPITAL, LLC acquired a new stake in LPTX for approximately $17,000. CUBIST SYSTEMATIC STRATEGIES, LLC purchased a new stake in LPTX valued at around $10,000 in the second quarter. In total, there are 85 active investors with 44.50% ownership of the company’s stock.
With an opening price of $0.4300 on Wednesday morning, Leap Therapeutics Inc. (NASDAQ: LPTX) set off the trading day. During the past 12 months, Leap Therapeutics Inc. has had a low of $0.42 and a high of $3.45. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 6.80, and a quick ratio of 6.80. The fifty day moving average price for LPTX is $0.6407 and a two-hundred day moving average price translates $1.1171 for the stock.
The latest earnings results from Leap Therapeutics Inc. (NASDAQ: LPTX) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.15, missing analysts’ expectations of -$0.1 by -0.05. This compares to -$0.14 EPS in the same period last year.
Leap Therapeutics Inc.(LPTX) Company Profile
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.